Immatics NV (IMTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $972.99M
Last updated: Nov 17, 2026 at 11:06 AM ET
Immatics NV (IMTX) Competitors
The companies most similar to Immatics NV are Immix Biopharma (IMMX), CureVac NV (CVAC) and Nektar Therapeutics (NKTR). By market cap, Immatics NV ranks 9th of the 13 companies on this page; Immunocore Holdings (IMCR) is the largest at $1.55B.
Peer Comparison
IMTX's revenue growth of 33.5% is above the peer median of -2.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immunocore Holdings Ltd (IMCR) | $1.55B | N/A | 2.8x | -7.5% | -0.5% | -1.4% | 0.00% |
| MoonLake Immunotherapeutics (MLTX) | $1.06B | N/A | N/A | 0.0% | -54.6% | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Jade Biosciences, Inc. (JBIO) | $1.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Peer median | $1.06B | 95.1x | 5.8x | 0.0% | -52.3% | -2.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to Immatics NV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| Nektar Therapeutics (NKTR) | Nektar Therapeutics is a biopharmaceutical company. | NKTR competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Immunocore Holdings Ltd (IMCR) | Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. | IMCR competitors |
| MoonLake Immunotherapeutics (MLTX) | MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug... | MLTX competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Jade Biosciences, Inc. (JBIO) | Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune... | JBIO competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
Frequently Asked Questions About IMTX
Who are Immatics NV's main competitors?
The companies most similar to Immatics NV include Immix Biopharma (IMMX), CureVac NV (CVAC), Nektar Therapeutics (NKTR), DBV Technologies (DBVT) and Theravance Biopharma (TBPH), listed from the closest match.
Who is Immatics NV's biggest competitor?
Immunocore Holdings (IMCR) is the largest of the similar companies at $1.55B; Immix Biopharma (IMMX) is the closest match by business profile, size, sector and industry.
How does IMTX stock compare with its competitors?
IMTX's P/S is 17.7x against a peer median of 5.8x; its net margin is 0.0% against a peer median of 0.0%.
Which of Immatics NV's competitors pays a higher dividend?
Immatics NV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Immatics NV bigger than its competitors?
No. Immatics NV is 9th by market cap among the 13 companies on this page; the largest is Immunocore Holdings (IMCR) at $1.55B.
IMTX pages: Overview, Financials, Competitors